INSUBCONTINENT EXCLUSIVE:
AstraZeneca Plc said the third phase trial of its top-selling cancer drug Tagrisso, aimed at showing the drug's benefit in lung cancer
treatment, will be unblinded early after a recommendation from an independent data monitoring committee.